EPALINGES, Switzerland – (COMMERCIAL THREAD) – A trial has shown that animal milk oligosaccharides (AMO) made by leading Swiss biotechnology experts Gnubiotics Sciences can help prevent the effects of antibiotics on the gut microbiome.
The state of the microbiome is critical to the health and well-being of all mammals, but the use of antibiotics can upset its delicate balance. This can have serious effects on animal health: Recent studies have shown that the alteration of the microbiome caused by antibiotics can increase the risk of colorectal cancer in humans.
In addition, there is also the very real problem of antibiotic resistance caused by overuse for routine and preventative treatments. As the number of pets has grown exponentially during the ongoing pandemic – today more than 85 million homes in Europe have at least one – antibiotic resistance is a growing concern.
However, help could be in sight for the animals and their owners. Key data from a recent study conducted at the Division of Nutritional Sciences at the University of Illinois, Urbana Cham page (UIUC) in collaboration with the College of Veterinary Medicine and Biomedical Sciences at Texas A&M University shows that AMOs made by Gnubiotics have helped protect the dog microbiome from the negative effects of the antibiotic metronidazole. The study of 12 beagles found that the microbiome of dogs treated with Gnubiotics’ AMO GNU-100 quickly picked up gut bacteria – such as Faecalibacterium prausnitzii, Bacteroids and Prévotella.
In addition, large groups of bacteria essential for a healthy gut biome, such as Bacteroides spp. and Prevotella spp. were protected from the effects of antibiotics in dogs treated with AMOs. In addition, the study shows that the microbiome of dogs given GNU-100 quickly regained all the diversity necessary for good gut health. However, the microbiomes of the beagles in the study that did not receive GNU-100 AMO never returned to their full diversity – and therefore to their full health – during the 16-week study.
Dr Jan Suchodolski, veterinary expert and microbiome specialist, Dr VetMed and professor of internal medicine for small animals at Texas A&M, said: “The gut microbiome is important to the health and condition of dogs and cats. The data from this study provides strong evidence not only of the negative impact of antibiotics on the gut microbiome, but also that data-driven solutions such as GNU-100 enable faster recovery and restoration of key commensals such as Bacteroides.
Yemi Adesokan, CEO and CSO at Gnubiotics commented, “We are excited and touched by this first-of-its-kind data and the underlying science that further shows the protective and restorative effect of our GNU-100 AMOs on altered gut microbiomes. antibiotics. We will continue to invest in clinical trials to understand the additional beneficial effects of GNU-100 on pet microbiome health and disease. ”
Gnubiotics Sciences is a Swiss biotechnology company with a growing pipeline of microbiome-targeted candidates designed for both animals and humans. Beyond its pipeline, Gnubiotics has also developed REVELAbiome ™, a proprietary ultra-high resolution sequencing technology that enables the detection and quantification of bacterial taxonomy down to the strain level. To learn more, please visit www.gnubiotics.com or follow us on LinkedIn @ www. https://www.linkedin.com/company/gnubiotics/.